Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 10/20 | 0.42 |
| ▸ | HTR2A | P28223 | 9/20 | 0.42 |
| ▸ | HTR2B | P41595 | 9/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2776752 | 0.91 | KDR (0.49) | KDRFGFR1HTR2CHTR2AHTR2B | |
| SCHEMBL12972340 | 0.90 | KDR (0.47) | KDRFGFR1MAPTTP53THRB | |
| SCHEMBL2782680 | 0.90 | HTR2C (0.42) | KDRFGFR1HTR2CHTR2AHTR2B | |
| SCHEMBL2782677 | 0.90 | HTR2C (0.42) | KDRFGFR1HTR2CHTR2AHTR2B | |
| SCHEMBL12972327 | 0.89 | KDR (0.47) | KDRFGFR1MAPTTP53THRB | |
| SCHEMBL2779084 | 0.89 | KDR (0.52) | KDRFGFR1RAF1HTR2CHTR2A | |
| SCHEMBL2777572 | 0.88 | KDR (0.43) | KDRFGFR1HTR2CHTR2AHTR2B | |
| SCHEMBL12972328 | 0.87 | KDR (0.47) | KDRFGFR1MAPTTP53THRB | |
| SCHEMBL12972329 | 0.87 | KDR (0.44) | KDRFGFR1MAPTTP53THRB | |
| SCHEMBL12972360 | 0.87 | KDR (0.47) | KDRFGFR1MAPTTP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855215-B2 | Cyclic diaryl ureas suitable as tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2010-12-21 | — | — | US | disclosed |
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | BOLD GUIDO | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039440-A1 | Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors | RET, ROS1, BRAF | KDR 479/4885FGFR1 915/4885MAPT 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.